ABSTRACT
Background: Since the beginning of the pandemic, our understanding of the hepatic repercussions of severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) infection and the resulting coronavirus disease 2019 has significantly progressed. Aim(s): The primary objective of this study was to characterize coagulation hemostasis in patients with COVID-19- associated liver cirrhosis. Method(s): Our study involved 200 patients (confirmed COVID-19 ) with liver cirrhosis, decompensation stage, Child-Pugh class V as the objects of study. I group consisted of 50 patients with liver cirrhosis of HBV etiology, II group 30 patients with HBV + HDV liver cirrhosis, III groups 50 patients with cirrhosis of unknown etiology. The control group consisted of 20 healthy individuals. All patients were tested for coagulogram. Result(s): In group I, activated partial thromboplastin time was 18.4 +/- 2.3 c, prothrombin time was 9.5 +/- 0.6 c, prothrombin index was 126 +/- 6.4, and MNO was 0.79 +/- 0.03. In group II, activated partial thromboplastin time was 15.2 +/- 1.1 c, prothrombin time was 8.2 +/- 0.4 c, prothrombin index was 146 +/- 8.2, and the international normalized ratio was 0.68 +/- 0.02. In group III, was 12.2 +/- 0.8 c, prothrombin time was 7.9 +/- 0.4 c, prothrombin index was 152 +/- 10.4, and the international normalized ratio was 0.66 +/- 0.02. In the control group, activated partial thromboplastin time was 32 +/- 1.8 c, prothrombin time was 12.1 +/- 0.2 c, prothrombin index was 99 +/- 3.7, and the international normalized ratio was 1.01 +/- 0.06. Conclusion(s): To summarize, our findings demonstrate that severe COVID-19 infection is associated with coagulopathy, which is associated with a bad prognosis. COVID-19 coagulopathy, on the other hand, does not appear to be a form of disseminated intravascular coagulation. Additional research is required to elucidate additional probable mechanisms of this coagulopathy, including a thorough examination of the fibrinolytic system.
ABSTRACT
Objective of the study: To study disorders of hemostasis in patients with COVID-19. Research materials: 200 patients with COVID-19 treated in departments of the 2nd Zangiata infectious diseases hospital. Research methods: PT, PTI, INR, APTT, fibrinogen, adhesion, aggregation and retraction of platelets. Research results: with COVID-19, there is an increase in platelet adhesion by 11.2-58.0%, aggregation by 21.9-60.0%, shortening of retraction by 12.5-31.2%, significant mixing of the three phases of coagulation hemostasis towards hypercoagulability. Conclusion: The displacement of hemostasis towards hypercoagulability was higher in patients with severe and extremely severe coronavirus infection. © 2021 Universitatea de Vest Vasile Goldis din Arad. All rights reserved.